A Phase I Dose Finding Study of MB-CART2219.1

This early-phase study is finding the right dose of MB-CART2219.1 — a dual-targeting CAR-T cell therapy that attacks both CD19 and CD22 proteins found on certain blood cancer cells. It is being tested in adults with lymphoma and in children/teenagers (12+) with B-cell acute lymphoblastic leukemia (B-ALL). **You may be eligible if (adults with lymphoma):** - You are 18 or older - Your cancer cells express CD19 or CD22 - You are able to follow study requirements and commit to 15-year follow-up (required by regulations for gene therapy) **You may be eligible if (pediatric B-ALL patients):** - You are 12 or older - You have B-cell acute lymphoblastic leukemia with CD19 or CD22 expression - Your parent or guardian has consented and you have also given assent **You may NOT be eligible if:** - Your cancer cells do not express CD19 or CD22 - You cannot commit to the required long-term follow-up - You have significant health conditions that would make this treatment unsafe Talk to your doctor to see if this trial is right for you.